Oncology The cancer community must seize the opportunity of the Natio... With the government’s National Cancer Plan due for publication this autumn, we have an opportunity to fundamentally improve how we deliver innovation.
Oncology ASCO 2025: Building a stronger future in cancer care with a ... From attending key oral sessions, clinical science symposiums and poster presentations to the simple pleasures of chatting with colleagues during coffee breaks, we left the
Oncology Servier’s ASCO 2025 data: Advancing IDH-mutated cancer treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
Oncology Single-cell multi-omics and oncological potential Just like people, no two cancer cells are alike.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.